EDITORIALS
Non-invasive ventilation for the treatment of hypercapnic respiratory failure in cystic fibrosis
Correspondence to:
Peadar G Noone, Pulmonary Division, CB# 7020, UNC Chapel Hill, NC 27599-7020, USA; pnoone@med.unc.edu
| The first 150 words of the full text of this article appear below. |
Median survival for patients with cystic fibrosis (CF) has improved steadily over the past several decades as a result of a multifaceted treatment approach to the disease.1 Despite this aggressive care, many patients with classic disease eventually develop respiratory failure from progressive airways obstruction and bronchiectasis.2 At this stage, treatment strategies may focus on alleviating both the symptomatic and physiological effects of respiratory failure. Initially respiratory failure may be mainly hypoxic (type 1: arterial oxygen pressure (PaO2) <8 kPa (or 60 mm Hg), with normal arterial carbon dioxide pressure (PaCO2)), and supplemental oxygen during sleep and/or exercise may be effective. However, when the disease becomes more severe, hypercapnia may ensue (type 2: PaCO2 >6 kPa (or 45 mm Hg)). Such patients with chronic respiratory failure usually have obvious clinical signs and symptoms, and blood gas analysis demonstrates a compensated respiratory acidosis.3 Thus it is important
This article has been cited by other articles:
-
Balfour-Lynn, I. M
(2009). Cystic fibrosis papers of the year 2008. JRSM
102: 29-35
[Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
